GET A QUOTE

Coagulation Factor V (F5): Essential Regulator of Blood Clotting Cascade

Molecular Structure and Biochemical Properties

Factor V is a glycoprotein weighing around 330 kDa. Is made as a single chain molecule with six unique domains organized in an A1-A2-B-A3-C1-C2 layout. The A domains have copper binding locations, for protein activity; the B domain is taken out during activation. The C domains play a key role in binding to membranes and interactions, between proteins.

After the protein matures undergoes translational changes such, as glycosylation and sulfation which are essential for its folding and functioning properly. The Factor V protein has characteristics like binding to phospholipid membranes in a calcium dependent manner and interacting with both activated protein C and Factor Xa specifically. The three-dimensional structure of the protein shows exposed sites that can be cleaved by thrombin for activation and inactivation, by activated protein C.

The molecule shows durability in the bloodstream. Stays active, for about 12 to 36 hours before breaking down completely This resilience is sustained by engaging with various plasma proteins and employing defence mechanisms to prevent early breakdowns comprehending Factor Vs functions, in blood clotting and creating treatment plans relies on understanding these physical and chemical characteristics deeply.

Synthesis, Activation, and Regulation

Factor V is primarily synthesized in the liver hepatocytes, although small amounts are also produced by megakaryocytes. The synthesis process involves complex cellular machinery ensuring proper protein folding and post-translational modifications. After synthesis, Factor V is secreted into the bloodstream as an inactive precursor (procofactor).

Activation occurs through proteolytic cleavage by thrombin or Factor Xa, resulting in the removal of the B domain and the formation of the active Factor Va. This activation process exposes critical binding sites and enhances the protein’s procoagulant activity. The activated form consists of a heavy chain (A1-A2 domains) and a light chain (A3-C1-C2 domains) held together by calcium ions.

Regulation of Factor V activity involves multiple mechanisms. Activated Protein C (APC) is the primary regulator, inactivating Factor Va through proteolytic cleavage at specific arginine residues. This inactivation is enhanced by Protein S and phospholipid surfaces. Additionally, various feedback mechanisms and inhibitors help maintain appropriate Factor V levels and activity in circulation.

Physiological Functions and Coagulation Cascade

Factor V plays a central role in the coagulation cascade as a critical cofactor for Factor Xa in the prothrombinase complex. Upon activation to Factor Va, it accelerates the conversion of prothrombin to thrombin by approximately 1000-fold. This amplification is essential for generating adequate thrombin levels necessary for stable clot formation.

In the prothrombinase complex, Factor Va acts as a receptor for Factor Xa on phospholipid surfaces, optimally positioning the enzymes and substrates for efficient catalysis. This assembly occurs primarily on activated platelet surfaces during the coagulation response.

Clinical Significance and Associated Disorders

Factor V disorders encompass both deficiencies and hypercoagulable states. Factor V deficiency (parahemophilia) is a rare inherited disorder characterized by mild to severe bleeding tendencies. The severity typically correlates with the degree of Factor V activity reduction. Symptoms may include easy bruising, menorrhagia, and post-surgical bleeding.

The Factor V Leiden mutation, affecting approximately 5% of Caucasians, represents a hypercoagulable state. This mutation makes Factor Va resistant to APC inactivation, increasing thrombosis risk. Heterozygous carriers have a 5-fold increased risk of venous thrombosis, while homozygotes face a 50-fold increased risk.

Acquired Factor V disorders can occur through autoantibody development or liver disease. These conditions may present with either bleeding or thrombotic complications, depending on the specific pathophysiology.

Diagnostic Methods and Therapeutic Implications

Factor V disorders diagnosis involves conducting both molecular tests to determine the presence of mutations such, as Factor V Leiden through assays like Factor V activity tests and activated protein C resistance assays alongside mixing studies, for accurate interpretation within the clinical setting.

The methods used to treat disorders differ depending on the condition involved. For Factor V deficiency cases fresh frozen plasma transfusions may be needed, before surgery or, in times of bleeding episodes. Although there is development of Recombinant Factor V it is not currently available, for use. In cases of Factor V Leiden and thrombotic disorders anticoagulation therapy is commonly required, with the duration and strength of treatment adjusted based on risk factors.

Monitoring patients progress is crucial, in situations where there are risks of both bleeding and blood clotting issues present. In the advancements in treatment could involve personalized methods and genetic therapy options that may provide more precise interventions, for Factor V related conditions.

Suitable ELISA Kits

Online Enquiry Form

"*" indicates required fields

Please check mark information required:

TESTIMONIALS arrow icon

Your secretory IgA ELISA gave good results and I was also really impressed with how quickly we received it.

L. Johnston
PhD Student / University of Glasgow

It is refreshing to know that you have a technical team that is very knowledgeable. I have already recommended your company to other researchers in our department.

Dr. P. Anderson
Lecturer / University College London (UCL)

I am a first time user and found that your instruction manual was very easy to follow. The insulin ELISA assay performed well and I was happy with the results that were generated.

J. Thomas
Senior Technician / Addenbrooke’s Hospital

I carried out a pilot study comparing the performance of many ELISA assay's from different suppliers and found your kits to be one of the better performers. We observed good linearity and tight replicates.

Dr. C. Davies
Lead Scientists / AstraZeneca

You are my first point of contact when I am looking to purchase ELISA. You have such an easy and simple system, yet it is very effective.

A. Shaw
Purchasing / University of Oxford